Royalty Report: Drugs, HIV / AIDs, Disease – Collection: 362455

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Drugs
  • HIV / AIDs
  • Disease
  • Drug Discovery
  • Vaccine
  • Cancer
  • HPV
  • Therapeutic
  • Immune

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 362455

License Grant
The University grants an exclusive, worldwide, right and license under the University Subject Technology to develop, make, have made, use, market, import, have imported, Sell, offer for Sale and have Sold any and all Licensed Products in the field and in the Territory.
License Property
The University owns certain intellectual property relating to the treatment of Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV).

Licensed Products means a product containing P-VL-FD4C that is developed, made, used, marketed, imported, Sold, or offered for Sale by Licensee, its Affiliates or any Sublicensees in any country of the Territory where the University owns or controls at least one Valid Claim covering the Subject Technology.

University Subject Technology shall mean all technology, trade secrets, know-how, methods of treatment, documents, materials, tests, all improvements thereto, and all proprietary information pertaining to the compound B-L-FD4C (2 ,3-dideoxy-2 ,3 -didehydro-B-L-5-fluorocytidine) or any 5- or N4 derivatives or products thereof.

Field of Use
Field means all human prophylactic and therapeutic applications with respect to HIV and HBV.

IPSCIO Record ID: 362454

License Grant
Pursuant to the terms of a certain License Agreement, by and between a University, the Licensors Designee in this agreement, and Licensor, the University and Licensor have agreed to grant Licensee a sublicense in certain inventions relating to ß-L-FD4C.

Licensor hereby grants to Licensee a non-transferable, worldwide, exclusive license under the Licensed Technology to make, have made, import, export, use, sell and have sold Licensed Products and practice the Inventions.

License Property
The University has licensed to Licensor certain inventions relating to, among other things, potential anti-viral compounds, including ß-L-FD4C.

The patents include
Novel L-23-Dideoxy Nucleoside Analogs as Anti-Hepatitis (HBV) Agents;
Reduced Toxicity Compositions and Methods for Treating HIV Infections; and,
Process for High Yield Diastereoselective Syntheses of Dideoxvnucleotides.

Field of Use
The field of use includes HIV treatments.

IPSCIO Record ID: 257474

License Grant
The original agreement is an exclusive license under Licensor patent rights and know-how to develop, make, have made, use and sell Licensed products in the Territory.
License Property
With this amendment, Licensed products shall also mean Treatment vaccines.  Treatment vaccines shall mean a bulk or finished vaccine.

The parties wish to further amend the Agreement to provide that Merck shall have rights to vaccine products for the treatment of patients infected with Human Immunodeficiency Virus and Hepatitis B Virus.

Field of Use
The field of use is for the treatment of Human Immunodeficiency Virus (HIV-1) and/or diseases caused by infection with HIV-I in humans and Hepatitis B Virus (HBV) and/or diseases caused by infection with HBV in humans, which utilizes the Technology or technology which is developed by Licensor during and as a result of the Research Collaboration Program.

IPSCIO Record ID: 289184

License Grant
The University Foundation grants to Licensee the exclusive right and license to make, have made, use, import, offer for sale, and sell in the Territory, Licensed Products during the term of this Agreement including Licensee’s right to grant sublicenses.

The license granted is subject to a reserved, non-exclusive license of Foundation, transferable to University and its not-for-profit academic collaborators, to practice the Licensed Patents in the Field, only for the purpose of non-commercial scientific inquiry, academic research, and education.

License Property
Licensed Product means any compound, product, service, or process in the Field, the manufacture, use, or sale of which, but for the license granted herein, would infringe at least one Valid Claim.

Licensed Patents means (i) the patent applications listed, (ii) the United States patents that may issue from the patent applications listed and from divisionals and continuations and continuations-in-part of such United States patents and patent applications, (iii) all foreign counterparts of such patent applications, and all patents that issue thereon anywhere in the world, including reexamined and reissued patents. Licensed Patents shall also mean any patent application having claims in the Field directed to an invention made in the laboratory of Dr. Vasu Nair six months or less prior to the Effective date, and (iv) with respect to the matters described in clauses (i), (ii) and (iii) above, all provisionals, renewals, re-examinations, patents of addition, supplementary protection certificates, extensions, restorations of patent terms, letters of patent, registration or confirmation patents and reissues of such patents or patent applications.

7,250,421 – Diketo acids with nucleobase scaffolds anti-HIV replication inhibitors targeted at HIV integrase

Indication shall mean the prevention, treatment or diagnosis of a condition, infection or disease caused by or associated with a specific virus in the Field. For example HIV Indication means the prevention, treatment or diagnosis of a condition, infection or disease caused by or associated with Human Immunodeficiency Virus (HIV) and HCV Indication means prevention, treatment or diagnosis of a condition, infection or a disease caused by or associated with Hepatitis C Virus (HCV).

Field of Use
Field means any and all anti-viral uses, including but not limited to prophylaxis, diagnosis or treatment of a condition, infection or disease associated with a virus, except the Field specifically excludes any anti-viral use associated with (a) the following DNA virus families  poxviridae, polyomaviridae, papillomaviridae, adenoviridae, and parvoviridae; and (b) all RNA viruses except for the following RNA virus families, which are specifically included in the Field  retroviridiae (for example HIV as defined below), flaviviridae (for example HCV as defined below), orthomyxoviridae, paramyxoviridae, and coronaviridae. In the event that Licensee terminates the Sponsored Research Agreement (“SRA”), a copy of which is attached as Appendix J, pursuant to paragraph 16(d) of the SRA, the Field of this License Agreement shall automatically be amended to exclude HCV.

IPSCIO Record ID: 227266

License Grant
The Licensor of Korea grants an exclusive option to enter into the License Agreement, exercisable during the Option Period.

For the Option to Negotiate, Licensor grants an exclusive option to negotiate with Licensor for a license in the Licensee Territory to the Compounds for purposes of treating HIV infection in humans (the HIV Option), exercisable during the Option Period.

For the scope of the License, Licensor grants exclusive rights, with the right to sublicense, under all Licensor Patent Rights and Know-How to develop, make, have made, use, register, offer to sell, sell, export and import the Compounds and Products in the Licensee Territory for purposes of treating chronic Hepatitis B Virus (HBV) infection in humans.

License Property
The compound is known as LB80380 for treating chronic Hepatitis B Virus (HBV) infection in humans, the compound designated LB80331, the compound designated LB80317, all salts, esters, prodrugs, intermediates and metabolites of LB80380, LB80331 or LB80317, any analogs or formulations as a human therapeutic for treatment of chronic HBV infection of LB80380, LB80331 or LB80317, whose manufacture, use, or sale would infringe a claim of an issued patent or pending application for a patent included in the Licensor Patent Rights; provided, however, that Licensor shall retain all rights to such analogs or formulations of LB80380, LB8033 l or LB80317 for all uses other than as a human therapeutic for treating chronic HBV infection; and all phosphorylated forms, tautomeric forms and steriochemical forms of either LB80380, LB80331 or LB80317.

Product means any pharmaceutical formulation for administration to humans to treat chronic HBV infection containing a Compound.

The patents are for Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same; (+)-trans-( I -phosphonometh oxy-2-alkyl cycolpropyl)methyl nucleoside.

Field of Use
The field of use is for treating chronic Hepatitis B Virus (HBV) infection in humans.

IPSCIO Record ID: 274922

License Grant
The Parties agreed to amend and restate several sections of the original agreement to include but not limited to the following

Licensor hereby grants non-exclusive licenses (other than the Co-exclusive License for Therapeutic Immunization for HPV Antigens granted in this Agreement C below) in accordance with the terms stated herein.

In consideration of the obligations assumed by Licensee hereunder, Licensor hereby grants to Licensee and to any affiliates of Licensee the following licenses without the right to sublicense as set forth in this paragraph under technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the territory and in the field all products and/or compinations, subject to the following

(A1) For prophylactic immunization within the field, Licensor grants a non-exclusive license for the following licensed antigens (including combinations thereof) and no other antigens.

HPV Antigens
HBV Antigens
Influenza Antigens
Chlamydia Antigens
Mycobacterium Antigens
RSV Antigens
Malaria Antigens
Steptococcus pneumonia Antigens

(A2) For prophylactic immunization within the field, Licensor grants to Licensee a non-exclusive license for the following licensed antigens and no other antigens.

HIV Antigens

(B) For therapeutic immunization within the field, Licensor grants Licensee a non-exclusive license for the following licensed antigens (including combinations thereof) and no other antigens.

HBV Antigens
Chlamydia Antigens
Mycobacterium Antigens

(C) For therapeutic immunization within the field, licensor grants Licensee a co-exclusive license for the following licensed antigens (including combinations thereof) and no other antigens.

HPV Antigens

The regulatory and development milestone payments and the patent royalties for each Licensed Antigen in the non-exclusive licenses granted in (A1) and (B) shall be reduced by a certain percent.

License Property
The Products are for therapeutic immunization relating to infectious diseases that such as

HBV  – hepatitis B virus
HPV – human papillomavirus
HIV – human immunodeficiency virus

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 362516

License Grant
The University grants to an exclusive, world-wide right and license, with the right to grant sublicenses, to make, have made, use, import, sell and offer for sale University Licensed Products.

This license grant is exclusive with respect to Universitys rights, except that University may use and permit other nonprofit organizations to use the University Patent Rights for educational and research purposes and not for sale or offer of sale.

License Property
The University controls certain intellectual property developed related to pathogenic viral proteins which control host cell functions.
Field of Use
Licensee is a biopharmaceutical company engaged in the discovery and development of drugs and DNA vaccines for the treatment of infectious diseases, including the HIV and hepatitis C viruses, as well as cancer and inflammatory diseases.

IPSCIO Record ID: 279299

License Grant
This agreement is to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets involved in HIV.

For the License of proprietary rights,  Licensor grants a co-exclusive, with Licensor, worldwide right and license, without the right to sublicense, within the Territory, to use the Licensor Intellectual Property and Licensor Patent Rights and the Program Intellectual Property owned by Licensor, in each case with application to the Field to the extent necessary or useful to research, develop, have developed, make, have made, use, distribute, promote, market, offer for sale, sell, have sold, import and export Designated Shared Compounds, Derivative Compounds thereof, Shared Products and, to the extent permitted Independent Compounds, Derivative Compounds thereof and Independent Products.

The research license portion is non-exclusive.

License Property
ALIS means the Automated Ligand Identification System, an automated, ultra-high throughput ligand selection system proprietary to Licensor that is used to identify multiple classes of chemical ligands against a target protein.

Licensor will screen at least five million (5,000,000) compounds contained in the Licensor NeoMorph Screening Library against each Shared Target.

Licensee will provide at least two hundred fifty (250) nmol. of each of the purified functionally-active Shared Target proteins.

Derivative Compounds means any analogs, homologs or isomers of a Designated Shared Compound and/or an Independent Compound, as applicable.

Field of Use
Field means all preventative, therapeutic and diagnostic uses of Shared Products or Independent Products with respect to human immunodeficiency virus (HIV) in humans.

Licensee is interested in identifying potential pharmaceutical products for the treatment of human immunodeficiency virus (HIV) and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets involved in HIV.

IPSCIO Record ID: 365329

License Grant
This amendment, included with this agreement, updates the financial terms, including the royalty rates.

By the original agreement, University grants to an exclusive, world-wide right and license, with the right to grant sublicenses, to make, have made, use, import, sell and offer for sale University Licensed Products.

This license grant is exclusive with respect to Universitys rights, except that University may use and permit other nonprofit organizations to use the University Patent Rights for educational and research purposes and not for sale or offer of sale.

License Property
The University controls certain intellectual property developed related to pathogenic viral proteins which control host cell functions.
Field of Use
Licensee is a biopharmaceutical company engaged in the discovery and development of drugs and DNA vaccines for the treatment of infectious diseases, including the HIV and hepatitis C viruses, as well as cancer and inflammatory diseases.

IPSCIO Record ID: 233457

License Grant
The Parties now revise certain terms and conditions of the Agreement to give effect to the Parties’ agreement that Swiss Licensee will take over control of Development, Commercialization and Manufacture of the LdT Product and related matters, on a worldwide basis.

With this amendment, the HBV License now reads as follows for the LdT License
– Subject to the terms and conditions of this Agreement,  Licensor grants to The Swiss Licensee a right and license, with the right to grant sublicenses as permitted, under Licensors rights in the Licensors Intellectual Property and in the Joint Intellectual Property to manufacture, have made, use, market and promote, import and export, offer for sale, sell and distribute the LdT Product in the Field within the Licensees Territory during the applicable Country Terms for the LdT Product.   The license granted to Licensee in this subsection shall be exclusive, even with respect to Licensor as to the Licensees Territory.

With this amendment,  EU Countries and Licensee takes over control of Development, Manufacture and Commercialization worldwide, and books sales.
– Licensee will pay royalties for the US Territory, the Major EU Countries and the Rest of World Territory.
– the Parties will terminate the existing Supply Agreement and the Commercial Manufacturing Agreement, along with some changes to other agreements.
– Licensor grants to Licensee a license to Manufacture worldwide.

This agreement has pediatric exclusivity terms and a non-exclusive grant back to Licensor.

License Property
LdT Product Patent Rights means those Licensor LdT Product Patent Rights, where Licensor is the patent owner, co-owner or licensee, including for the avoidance of doubt, pediatric exclusivity terms.

The patents cover
– Methods of Treating Hepatitis Delta Virus Infection with Beta-L-2- Deoxynucleosides
– Crystalline and Amorphous Forms of B-L-2-Deoxythymidine
– B-L-2-Deoxynucleosides for the Treatment of Lamivudine-Resistant
– Industrially Scalable Nucleoside Synthesis
– Synthesis of Beta-L-2- Deoxynucleosides
– B-L-2-Deoxypyrimidine Nucleosides for the Treatment of Hepatitis B, and,
– Methods of Manufacture of 2-Deoxy-B-L-Nucleosides

Field of Use
Licensor is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases. The Company’s current focus is on diseases caused by hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

IPSCIO Record ID: 158370

License Grant
The Licensee received an exclusive license to all of the Korean Licensors rights to L-FMAU technology for use in the hepatitis B virus ('HBV') field as well as all other human antiviral applications. The Licensor may grant sublicenses.
License Property
L-FMAU is a pyrimidine nucleoside analogue that has been shown to be a potent inhibitor of HBV replication in vitro.
Field of Use
The Licensee shall make, have made, use, import, offer for sale, sell and have sold Licensed Products (including, but not limited to, Bulk Drug Substance) in the Territory during the term.

IPSCIO Record ID: 289819

License Grant
Licensor hereby grants to Licensee an exclusive royalty-bearing license (or sublicense, as the case may be), under the Licensor Patents, the Licensor  Know-How and the Inventions (if any) solely to Commercialize, use, have used, offer for sale and sell Licensed Products in the Field in the Territory.

With this agreement, Licensor will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications, while Licensee has been granted an exclusive license to market and distribute leronlimab.

License Property
Leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.

Licensor has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (“HIV”) infection, as well as related HIV infection indications.

Field of Use
The field of use is for the treatment of HIV.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.